Drug Trial Radar · NCT06111586
Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
197
Actual
Start
Dec 11, 2023
Primary completion
Apr 28, 2027
Study completion Oct 29, 2030
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, parallel group, double-blind Phase 2 study with a blinded extension evaluating the safety and efficacy of 3 dose levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin treatment. Study details include: Screening period: at least 3 weeks and up to 5 weeks. Enrollment date of the participant must take into consideration this constraint) Double-blind treatment period 104 weeks: Main treatment period: 52 weeks Blinded extension: 52 weeks Optional OLE period: 104 weeks Safety follow-up: 26 weeks The treatment duration will be up to 104 weeks , the total study duration will be up to 135 weeks for Part A and Part B. If participants enter the OLE period, the treatment duration will be up to approximately 208 weeks , and the total study duration will be 240 weeks approximately .
Conditions
- Type 1 Diabetes Mellitus
Interventions
FrexalimabDrug
IV Infusion at Day 1 SC Injection from W2 to W102
PlaceboDrug
IV Infusion at Day 1 SC Injection from W2 to W102
InsulinDrug
SC injection, dose and frequency will be established and/or adjusted by investigator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in mean 2h mixed meal tolerance test (MMTT) stimulated C-peptide concentration, calculated from AUC from baseline to W52 for Part B (12-21 y.o.)Time frame: Baseline to Week 52
Locations
79 sites in 16 countries. Site status is shown where the registry gives one.
University of California San Francisco - Mission Bay- Site Number : 8400012
San Francisco, California
University of Colorado - Anschutz Medical Campus- Site Number : 8400003
Aurora, Colorado
University of Florida College of Medicine- Site Number : 8400010
Gainesville, Florida
University of Miami Hospital- Site Number : 8400013
Miami, Florida
AdventHealth Orlando- Site Number : 8400002
Orlando, Florida
Rocky Mountain Diabetes and Osteoporosis Center- Site Number : 8400009
Idaho Falls, Idaho
NorthShore University Health System - Endeavor Health Medical Group - Skokie - Woods Drive- Site Number : 8400007
Skokie, Illinois
Joslin Diabetes Center - Boston- Site Number : 8400015
Boston, Massachusetts
University at Buffalo - Downtown Campus- Site Number : 8400004
Buffalo, New York
University of North Carolina at Chapel Hill- Site Number : 8400001
Chapel Hill, North Carolina
Cincinnati Children's Hospital Medical Center- Site Number : 8400019
Cincinnati, Ohio
The Children's Hospital of Philadelphia Site Number : 8400005
Philadelphia, Pennsylvania
University of Texas - Southwestern Medical Center- Site Number : 8400011
Dallas, Texas
Benaroya Research Institute at Virginia Mason- Site Number : 8400016
Seattle, Washington
Investigational Site Number : 0400002
Graz, Austria
Investigational Site Number : 0400004
Linz, Austria
Investigational Site Number : 0400001
Vienna, Austria
Investigational Site Number : 0560002
Brussels, Belgium
Investigational Site Number : 0560001
Leuven, Belgium
Investigational Site Number : 1240001
Vancouver, British Columbia, Canada
Investigational Site Number : 1240007
London, Ontario, Canada
Investigational Site Number : 1240005
Montreal, Quebec, Canada
Investigational Site Number : 1240004
Montreal, Quebec, Canada
Investigational Site Number : 1240003
Montreal, Quebec, Canada
Investigational Site Number : 2030003
Ostrava, Czechia
Investigational Site Number : 2030002
Prague, Czechia
Investigational Site Number : 2030001
Prague, Czechia
Investigational Site Number : 2080005
Herlev, Denmark
Investigational Site Number : 2460001
Helsinki, Finland
Investigational Site Number : 2460004
Oulu, Finland
Investigational Site Number : 2460003
Tampere, Finland
Investigational Site Number : 2460002
Turku, Finland
Investigational Site Number : 2500004
Corbeil-Essonnes, France
Investigational Site Number : 2500005
Mont-de-Marsan, France
Investigational Site Number : 2500006
Paris, France
Investigational Site Number : 2500007
Pontoise, France
Investigational Site Number : 2500003
Saint-Herblain, France
Investigational Site Number : 2760003
Dresden, Germany
Investigational Site Number : 2760001
Hanover, Germany
Investigational Site Number : 2760002
Oldenburg in Holstein, Germany
Showing 40 of 79 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.